Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Mental or Behavioral Dysfunction > Hypochondriasis

Hypochondriasis

Hypochondriasis: A mental disorder characterized by an exaggerated or irrational belief that one has a serious illness, despite medical evaluation and reassurance.
Individuals with hypochondriasis are preoccupied with the idea that minor physical symptoms or bodily functions are signs of a severe illness, often seeking repeated medical attention and testing.
This condition can significantly impact a person's quality of life and daily functioning.
Effective management may involve a combination of cognitive-behavioral therapy and, in some cases, medication.
Understanding the nuances of this condition can enhance research efforts and improve outcomes for those affected by this perplexing mental health challenge.

Most cited protocols related to «Hypochondriasis»

1
Defining Clinical Features and Criteria
Cited 12 times
The first step is to clearly define the clinical feature of interest and establish inclusion and exclusion criteria. This requires clinical input, particularly from general practitioners (GPs) who are best placed to understand how clinical features are coded in a primary care setting. For rare conditions, which GPs encounter infrequently, it may also be important to get clinical input from hospital specialist doctors. Reliable sources of clinical information should be used, for example:

International Classification of Primary Care (ICPC), which defines symptoms and diagnoses, provides synonyms for them and, importantly, lists what should be excluded from the definition.10

The BMJ Best Practice guidelines (http://bestpractice.bmj.com/best-practice/welcome.html).

National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries (http://cks.nice.org.uk/).

ICD-10 (http://apps.who.int/classifications/icd10/browse/2016/en) – this is less useful for symptoms, as it focuses on diseases.

Medical Subject Headings (MeSH) (https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html).

National Health Service (NHS) Digital Technology Reference data Update Distribution: https://isd.digital.nhs.uk/trud3/user/guest/group/0/home. Downloadable technology reference files including READ Code Browers with cross-map files.

Other potential resources include patient support groups, online discussion forums and already published codelists (eg, https://clinicalcodes.org). Hierarchical classifications such as Read, Systematized Nomenclature of Medicine (SNOMED) or ICD-10 may be useful for identifying additional search terms and synonyms.
For some symptoms, it is necessary to tailor the definition to the context of the disease under investigation. Abdominal pain is a good example, where pancreatic disease may cause pain in the epigastrium and left hypochondrium, whereas disorders in the sigmoid colon generate pain in the left iliac fossa.
Watson J., Nicholson B.D., Hamilton W, & Price S. (2017). Identifying clinical features in primary care electronic health record studies: methods for codelist development. BMJ Open, 7(11), e019637.
Full text: Click here
Publication 2017
Abdominal Pain Colonic Diseases CTSB protein, human Diagnosis Fossa, Iliac General Practitioners Health Services, National Hypochondriasis Pain Pancreatic Diseases Patients Physicians Primary Health Care Rare Diseases Sigmoid Colon Specialists
2
Expanded Diagnostic Screening for Major Depression
Cited 10 times
In the CIDI-SF Major Depression (MD) section there are two ways to meet the diagnostic stem requirement: either to endorse questions about having two weeks in a row of dysphoric mood (CIDI-SF questions No. A1-A1a-A1b) or to endorse questions about having two weeks of anhedonia (A9-A9a-A9b), lasting most of day, nearly everyday. If the diagnostic stem requirement is achieved, two identical series of additional symptom questions are asked both for respondents who endorse the dysphoric mood stem series or the anhedonia stem series. These additional questions refer to 1) losing interest (A1c; A9a and A9b), 2) feeling tired (A1d; A9c), 3) change in weight (A2b; A10b), 4) trouble with sleep (A3a; A11a), 5) trouble concentrating (A4; A12), 6) feeling down (A5; A13), and 7) thoughts about death (A6; A14). A subject is considered likely to have the disorder if he/she endorses questions about having dysphoric mood and 3 questions or more about having these additional symptoms or if he/she endorses questions about having anhedonia and 2 questions or more about having additional symptoms except losing interest.
In the HPQ [see Additional file 1], some modifications in content and layout innovations were done:
- four questions about hypochondria, restlessness, sense of guilt, and hopelessness were added;
- the response categories of the questions about having dysphoric mood and anhedonia, that in the CIDI-SF are dichotomous (yes/no), have been modified to evaluate also current and lifetime prevalence rates and sub threshold disorders (MD symptoms with less duration and frequency);
- the questions about how much longer respondents have had dysphoric mood and/or anhedonia were inserted into a box placed just below the stem questions (questions No. 12 e 13). Instructions are made to go into this box either respondents have felt sad, blue or depressed and/or they have had lost interest on most things in the past month or in the past year. A slight modification was made in the response categories for dysphoric mood/anhedonia persistence that in original CIDI-SF were 'every day' 'almost every day' 'less often'. In this box, the individuals are also asked to report how many of the listed additional symptoms they have had during the 2 week period when feelings were worst;
- one question about difficulty to control over the symptoms (in the CIDI-SF this topic is assessed only for the Generalized Anxiety Disorder) was added;
- the two CIDI-SF questions evaluating contact with a doctor and contact with any other professionals were combined into a question that was inserted into the box together with the questions for evaluating use of medication, drugs or alcohol, and interference with daily functioning. Here and in any other relevant sections of the questionnaire, respondents are also asked about the amount of distress that could be caused by mental problems.
Gigantesco A, & Morosini P. (2008). Development, reliability and factor analysis of a self-administered questionnaire which originates from the World Health Organization's Composite International Diagnostic Interview – Short Form (CIDI-SF) for assessing mental disorders. Clinical Practice and Epidemiology in Mental Health : CP & EMH, 4, 8.
Full text: Click here
Publication 2008
Anhedonia Anxiety Disorders BAD protein, human Depressive Symptoms Diagnosis Ethanol Feelings Guilt Hypochondriasis Innovativeness Major Depressive Disorder Mood Pharmaceutical Preparations Physicians Respiratory Diaphragm Sadness Sleep Stem, Plant Thinking
3
Alexithymia, Interoceptive Awareness, and Hypochondriasis
Cited 8 times
All participants completed three questionnaires assessing: (i) IA, (ii) the ability to identify and describe emotions, and (iii) attitudes associated with hypochondriasis. To assess IA, and to specifically investigate how and how frequently subjects feel signals arising from their own body, we used an extended version of the “How do you feel questionnaire” (Grossi et al., 2014 (link)). The questionnaire included 35 items (Appendix 1) to be rated on a 5-point Likert scale (0 = never; 1 = sometimes; 2 = often; 3 = very often; 4 = always). The total score ranges 0–140, with higher scores meaning higher IA. In a preliminary study on an independent sample of 50 healthy students, we required participants to rate whether each item was clearly comprehensible and whether it assessed common physical sensations. All items were considered simple to comprehend, and suitable to address bodily sensations; all 35 items were thus included in the SAQ.
To assess the ability to identify and describe emotions, we used the Toronto Alexithymia Scale-20 items (TAS-20; Bagby et al., 1994 (link)), the most widely used self-report tool to assess the Alexithymia construct. The 20 items explore three factors reflecting the main aspects of the alexithymia: difficulty in identifying feelings; difficulty in describing feelings; externally oriented thinking. Each item has to be rated on a 5-point Likert scale (from 1 = “completely agree” to 5 = “strongly disagree”). The total score ranges 20–100, with higher scores indicating higher levels of alexithymia. The Italian version of TAS-20 has been demonstrated to show good test-retest reliability (0.86) and adequate internal consistency (Cronbach's alpha: 0.75) in a wide sample of healthy adults and of medical and psychiatric outpatients (Bressi et al., 1996 (link)).
The Illness Attitude Scale (IAS; Kellner, 1987 ) investigates attitude, fear and beliefs associated with hypochondriac behavior, and includes 27 items rated on a 5-point Likert scale (from 0 = “no” to 4 = “most of the time”). The total score ranges 0–108, with higher scores indicating more severe hypochondriac symptoms. The IAS is a reliable instrument, distinguishing hypochondriac patients from psychiatric patients and healthy individuals (Kellner, 1987 ). The IAS has been translated in several languages and its psychometric properties are well established (Sirri et al., 2008 (link)); an Italian version of the scale has been used in studies on clinical samples (e.g., Fava et al., 2000 (link)), but its psychometric properties have not been assessed specifically.
The study was approved by the Local Ethics Committees.
Longarzo M., D'Olimpio F., Chiavazzo A., Santangelo G., Trojano L, & Grossi D. (2015). The relationships between interoception and alexithymic trait. The Self-Awareness Questionnaire in healthy subjects. Frontiers in Psychology, 6, 1149.
Full text: Click here
Publication 2015
Adult Alexithymia Emotions Fear Feelings Human Body Hypochondriasis Outpatients Patients Physical Examination Psychometrics Regional Ethics Committees Student
4
Assessing Frequent Attenders in Finnish Healthcare
Cited 4 times
The study was conducted in four municipal health centres (Ii, Pudasjärvi, Utajärvi, Vaala) in Northern Finland.
The data on high utilizers of health care were collected retrospectively from the medical records of municipal health centres and medical reports from outpatient visits to Oulu University Hospital (providing secondary health care facilities for all of the municipal health centres participating in this study) before two years of study in 2006–2008. The patients’ inclusion criteria were being at least 18 years of age and having ≥ 8 visits per year to the general practitioner (GP) in the local health centre or ≥ 4 visits per year to the university hospital. The total number of all frequent attenders (FA) in the selected health centres during 1 August 2006–31 July 2008 was 3319 (see Figure 1).
Exclusion criteria included visits due to pregnancy or delivery, serial treatment for the same illness, terminal hospice, cancer palliative care, psychotic illness, dementia, mental retardation, inability to give informed consent, and other study intervention at the same time or just prior to this study.
All the participating health centres had a nurse as a case manager, who telephoned the identified FA and invited him/her to a consultation. The case manager verified patients’ eligibility for the study, requested their written informed consent for the study, and helped in filling in a semi-structured postal questionnaire, which was sent to the participants in October 2008 to May 2009.
The group for the case management intervention consisted of 286 patients (Ii = 61, Pudasjärvi = 90, Utajärvi = 56, Vaala = 79). In 2012, case managers called the patients still living in the area and asked about their willingness to participate in a psychiatric interview. Before the clinical interview, a new written informed consent was obtained and patients filled in the Finnish translation of the seven-item generalized anxiety disorder scale (GAD-7) (8), as well as a self-questionnaire concerning their lifetime psychiatric diagnoses and medications. A trained general practitioner carried out Mini International Neuropsychiatric Interview 5.0.0 Finnish version (MINI) with those 150 patients who gave written informed consent.
The group of patients attending the MINI interview did not differ significantly from the group not attending the interview regarding the following variables carried out earlier during the whole study project: quality of life measured by 15D, hypochondria measured by the Whiteley Index (WI), daily functioning measured by the Frenchay Activities Index (FAI), somatization measured by the somatization scale of the Symptom Checklist-90-R, orientation measured by the Sense of Coherence Scale (SOC), and mood measured by Raitasalo's modification of the short form of the Beck Depression Inventory (RBDI).
GAD-7 is a brief self-questionnaire developed based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) symptom criteria for GAD (8). It asks how often the patient has been bothered by seven different symptoms of anxiety during the last two weeks with response options such as: “not at all”, “several days”, “more than half the days”, and “nearly every day” scored as 0, 1, 2, and 3, respectively (8). The Finnish translation of GAD-7 has been done by Finnish psychiatry professionals.
Kujanpää T., Ylisaukko-Oja T., Jokelainen J., Hirsikangas S., Kanste O., Kyngäs H, & Timonen M. (2014). Prevalence of anxiety disorders among Finnish primary care high utilizers and validation of Finnish translation of GAD-7 and GAD-2 screening tools. Scandinavian Journal of Primary Health Care, 32(2), 78-83.
Publication 2014
Anxiety Case Management Case Manager Dementia Diagnosis, Psychiatric Eligibility Determination Hospice Care Hypochondriasis Intellectual Disability Malignant Neoplasms Mental Disorders Mood Nurses Obstetric Delivery Outpatients Palliative Care Patients Pharmaceutical Preparations Pregnancy Sense of Coherence
5
Suicidal Ideation Factors and Depression Symptom Profiles
Cited 4 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Anorexia Anxiety Barakat syndrome Compulsive Behavior Depersonalization Diagnosis Diploid Cell Dyssomnias Epistropheus Fatigue Genitalia Guilt Hypochondriasis Libido Medically Unexplained Symptoms Mood Obsessions Paranoia Pessimism Physicians Psychological Inhibition Sadness Satisfaction SCID Mice SERPINA3 protein, human Sleep Sleeplessness Stomach

Most recents protocols related to «Hypochondriasis»

1
Measuring Depression Severity with HAM-D before and after Brexanolone

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Anxiety brexanolone Diagnosis Diploid Cell Genitalia Guilt Hypochondriasis Mood Sleeplessness
2
Wearable Biosensors for Pediatric Disease Severity
The dataset for this work was sourced from two Institutional Review Board (IRB)-approved studies: (1) The Triheptanoin-clinical trial [27 ] (2) The Outcome measures and biomarkers development study [28 ]. The data were collected between January 2016 and December 2018—a three-year period. We used the body-worn patch BioStamp® (MC10 Inc., Cambridge, MA, USA) [29 ] to record ECG and three-axis acceleration from all the participants. While some ECG records were captured at a sampling rate of 125Hz, others were captured at a sampling rate of 250Hz. Concurrently, the three-axis acceleration records were captured at the sampling rates of 31.25Hz and 62.5Hz, respectively. These differences did not meaningfully influence the HRV and activity metrics we extracted [30 ]. We captured the ECG signal and the three-axis acceleration from the following four locations on the body: (1) Medial chest, (2) Left Hypochondrium, (3) Right Hypochondrium, and (4) Left Pectoralis. Per the protocols, all four locations were not used for all the participants, and only a subset of these locations was used for each participant. In conjunction to the signal data obtained from the biosensors, caretaker and physician surveys were conducted to obtain symptom severity for all 20 patients enrolled in the study. Specifically, the CGI-S scores were obtained through physician surveys to assign a binary label (low-severity vs. high-severity) for each patient-visit. A patient-visit was assigned to the low-severity category if the CGI-S ≤4 and was assigned to the high-severity category if the CGI-S >4. For each patient-visit we needed two consecutive days of signal data for the feature extraction. By applying this filter, we obtained a total of 32 patient-visits with two consecutive days of signal data and the associated CGI-S label. Among the 32 patient-visits, we had 18 high-severity visits corresponding to 10 unique patients and 14 low-severity visits corresponding to 11 unique patients. One patient had both low-severity and high-severity visits. We considered each patient-visit a data point and had a total of 32 data points with an associated binary label for model development and analysis. The racial, ethnic and age breakdown of the study subjects are illustrated in Fig 2A–2C respectively. The low and the high-severity groups had a similar split in patients with respect to the race, ethnicity and age. We had 8 patients each in low and high-severity groups whose race was “Caucasian” and 2 patients each in the two groups who’s race was “Asian”. One patient’s race was unknown. Further, we had 8 patients each in low and high-severity groups whose ethnicity was “Non-Hispanic” and 2 patients each in the two groups whose race was “Hispanic”. One patient’s race was unknown. Finally, the median age at enrollment in the low and high-severity groups were 8.5 and 8 years respectively.
Suresha P.B., O’Leary H., Tarquinio D.C., Von Hehn J, & Clifford G.D. (2023). Rett syndrome severity estimation with the BioStamp nPoint using interactions between heart rate variability and body movement. PLOS ONE, 18(3), e0266351.
Full text: Click here
Publication 2023
Acceleration Asian Persons Biological Markers Biosensors Catabolism Caucasoid Races Chest Epistropheus Ethics Committees, Research Ethnicity Hispanics Human Body Hypochondriasis Patients Pectoralis Muscles Physicians triheptanoin
3
Evaluating Persistent Physical Symptoms and Psychological Factors
The Persistent Physical Symptom Checklist (PPSC) is a self-report screening instrument that measures persistent problems with seven types of physical symptoms, i.e., sleep problems, pain, chronic tiredness fatigue or muscle problems, gastrointestinal problems, heart and chest symptoms, dizziness and/-or related problems and gynaecological problems. Respondents were asked whether they have had problems with a particular symptom for more than six months (one month for sleep problems), whether their symptoms have a known cause, and if so, what is the cause for their problems. The reported causes were considered and coded according to whether they included a possible medical explanation for their symptoms. They were then asked to rate on a 9-point scale the extent to which their problems interfere with their lives. The criteria for a particular PPS are considered met if the problem has been present for more than six months, did not have a clear defined medical cause and was definitely interfering with the respondent’s life (≥4 points). An evaluation of the checklist in an internal sample of 55 participants showed adequate convergent validity.
The Short Health Anxiety Inventory (SHAI) [42 (link),43 (link)] measures health-related anxiety. A cut-off score of 18 has been shown to reliably identify people meeting the DSM-IV hypochondriasis criteria. The scale has good psychometric properties [43 (link),44 ], and in this sample, Cronbach’s alpha was 0.88.
The Patient Health Questionnaire-9 (PHQ-9) [45 (link),46 ] measures depression severity over a two week period [47 (link)]. It has cut-off points of 5, 10, 15 and 20 (interpreted as mild, moderate, moderately severe and severe depression). The scale has good psychometric properties [45 (link),46 ], and in this sample, Cronbach’s alpha was 0.71.
The Generalised Anxiety Disorder-7 (GAD-7) [48 (link),49 ] measures general anxiety. It has cut-off points at 5, 10 and 15 (interpreted as mild, moderate, and severe anxiety). The scale has good psychometric properties [48 (link),49 ], and in our sample, Cronbach’s alpha was 0.92.
The Perseverative Thinking Questionnaire (PTQ) [50 (link)] measures self-reported rumination. The scale has 15 items, a total score that ranges from 0 to 75 and three subscale scores. Only the total score was used in this study. The original PTQ has good psychometric properties [50 (link)] and Cronbach’s alpha was 0.97 in our sample.
Flóvenz S.Ó., Salkovskis P., Svansdóttir E., Karlsson H.D., Andersen K, & Sigurðsson J.F. (2023). Non-Cardiac Chest Pain as a Persistent Physical Symptom: Psychological Distress and Workability. International Journal of Environmental Research and Public Health, 20(3), 2521.
Full text: Click here
Publication 2023
Anxiety Anxiety Disorders Chest Dyssomnias Fatigue Heart Hypochondriasis Muscle Tissue Pain Physical Examination Psychometrics Rumination, Digestive
4
Assessing Psychopathology in Somatic Symptom Disorder
We retrospectively reviewed the records of children hospitalized with a diagnosis of SSD from January 1, 2018, to December 31, 2021. Diagnoses of SSD were made by clinical psychologists or pediatric neuropsychiatrists trained in the field of somatic symptoms and related disorders in the developmental age, according to DSM-5 criteria. The psychopathological assessment of the included patients was performed using three standardized measures, validated for the use in children and adolescents in the Italian language:

Children’s Depression Inventory (CDI) is a self-assessment scale for depressive symptoms that can be administered to subjects of developmental age, between 8 and 17 years. It is made up of 27 items, with three alternative possibilities of response, graded on a scale from 0 to 2 points with increasing severity of the symptoms, which the subject is invited to choose based on the feelings of the previous 2 weeks; the total score will be between 0 and 54 points. It can be administered both individually and collectively and it can be completed in 15 min [21 ].

Self-Administered Psychiatric Scales For Children And Adolescents (SAFA) is a self-administered psychometric tool used to assess psychiatric comorbidities in children and adolescents. It is made up of six scales with different versions depending on the age group: 8–10 years “e”; 11–13 years “m”; 14–18 years “s.” It consists of an anxiety rating scale (SAFA-A), a depression rating (SAFA-D), an obsessive–compulsive symptom (SAFA-O), a psychogenic eating disorder (SAFA-P), one for somatic symptoms and hypochondria (SAFA-S), and finally one for phobias (SAFA-F) [22 ].

Revised Children’s Manifest Anxiety Scale—Second Edition (RCMAS-2) is a self-report tool consisting of 49 items to be administered both individually and in groups, which allows assessing the level and nature of the anxiety of children and young people aged 6 to 19. Through dichotomous questions, scores are provided for six distinct scales: physiological anxiety (FIS); concern (PRE); social anxiety (SOC); total anxiety index (TOT); defensive attitude (DIF); inconsistency index in responses (INC) [23 ].

Pruccoli J., Biagi C., Andreozzi L., Fetta A., Sacrato L., Tartarini C., Cordelli D.M, & Lanari M. (2023). Clinical and psychopathological profiles of children with somatic symptom disorders in a pediatric emergency unit: an observational study before and during the SARS-CoV-2 pandemic. European Journal of Pediatrics, 182(4), 1731-1739.
Publication 2023
Adolescent Age Groups Anxiety Child Depressive Symptoms Developmental Disabilities Diagnosis Feelings Hypochondriasis Medically Unexplained Symptoms Patients Phobias physiology Psychometrics Self-Assessment Social Anxiety Somatoform Disorder
5
Identifying and Treating Mental Disorders in Primary Care
The CIDI case definition included all threshold diagnoses assessed. Depressive disorders category included current depressive episode, recurrent depressive disorder and dysthymia. Anxiety disorders included general anxiety disorder, panic disorder, agoraphobia, PTSD, OCD and SP. Somatization disorders included somatization disorder, hypochondriasis, and neurasthenia. Somatoform pain disorder was not included due to issues of validity.
The rate of GP detection by the GPs of the patients’ mental health problems was defined as the percentage of patients detected by the GPs among patients having a psychiatric diagnosis according to the CIDI or among patients positive according to the GHQ-12—a score of 4 or above, as in a number of other studies, indicating a probable case or psychological distress; the use of the GHQ increased the power of the analysis because, as described above, many more patients filled the GHQ than the CIDI. The accuracy of GPs’ diagnosis, first defined as the percent of GP diagnosed patients with a given diagnosis among patients suffering from this diagnosis according to the CIDI was poor. GPs often diagnose mental disorder without specification and, while they indicated only one diagnosis, the comorbidity between diagnostic groups according to the CIDI was very high in this sample [2 (link)]. We therefore only examined GP detection of any disorder (GP+), separately among patients with depressive disorders, anxiety disorders and somatization disorders according to the CIDI.
When a patient was considered by the GP as a case, the treatment given was indicated on the Encounter Form. Treatment was classified as non-pharmacological or pharmacological. The former included: no non-pharmacological treatment; general psychosocial intervention (giving practical/social help, referral to nurse or social worker); referral to mental health professional (mostly MHS); counseling (discussing problems or giving advice); other (included further physical investigation and other non-psychosocial interventions). Psychopharmacological treatment categories included: no psychopharmacological treatment, sedatives (anxiolytics, tranquilizers, hypnotics), antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, selective noradrenaline reuptake inhibitors) and antipsychotic drugs, as well as other treatments (non-psychotropic drugs, such as vitamins, herbs or analgesics).
Treatments were analyzed for GP+ cases and GP defined depressive cases, anxiety cases and cases with different categories of somatoform symptoms and disorders.
Laufer N., Zilber N., Jeczmien P., Gilad R., Gur S, & Munitz H. (2023). Effect of implementation of mental health services within primary care on GP detection and treatment of mental disorders in Israel. Israel Journal of Health Policy Research, 12, 4.
Full text: Click here
Publication 2023
Agoraphobia Analgesics Anti-Anxiety Agents Antidepressive Agents Antipsychotic Agents Anxiety Disorders Diagnosis Diagnosis, Psychiatric Disorder, Depressive Dysthymic Disorder Hypnotics Hypochondriasis inhibitors Mental Disorders Mental Health Mentally Ill Persons Neurasthenia Norepinephrine Nurses Pain Pain Disorder Panic Disorder Patients Pharmacotherapy Physical Examination Post-Traumatic Stress Disorder Psychological Distress Psychotropic Drugs Sedatives Selective Serotonin Reuptake Inhibitors Somatization Disorder Somatoform Disorder Tranquilizing Agents Tricyclic Antidepressive Agents Vitamins Worker, Social

Top products related to «Hypochondriasis»

1
Multicentrum by GlaxoSmithKline
Sourced in United States
Multicentrum is a laboratory equipment product designed for use in scientific research and analysis. It is a multi-well plate or microplate that allows for the simultaneous processing and analysis of multiple samples or reactions in a single device.
2
Spss v20 by IBM
Sourced in United States, Germany, United Kingdom, Belgium, Japan, China, Austria, Denmark
SPSS v20 is a statistical software package developed by IBM. It provides data management, analysis, and visualization capabilities. The core function of SPSS v20 is to enable users to perform a variety of statistical analyses on data, including regression, correlation, and hypothesis testing.
3
Vevo 2100 by Fujifilm
Sourced in Canada, United States, Japan
The Vevo 2100 is a high-resolution, real-time in vivo imaging system designed for preclinical research. It utilizes advanced ultrasound technology to capture detailed images and data of small animal subjects.
4
Ingenia by Philips
Sourced in Netherlands, Germany, United States, Switzerland, Japan
The Philips Ingenia is a magnetic resonance imaging (MRI) system designed for diagnostic imaging. It provides high-quality images of the body's internal structures to aid in the detection and diagnosis of various medical conditions.
5
Spss statistics 22 by IBM
Sourced in United States, Japan, Germany, United Kingdom, Belgium, Austria, Australia, China, Switzerland
SPSS Statistics 22 is a statistical software package developed by IBM. It provides tools for data management, analysis, and presentation. The software includes features for descriptive statistics, regression analysis, and hypothesis testing.
6
Spss version 22 by IBM
Sourced in United States, Japan, United Kingdom, Austria, Germany, Czechia, Belgium, Denmark, Canada
SPSS version 22.0 is a statistical software package developed by IBM. It is designed to analyze and manipulate data for research and business purposes. The software provides a range of statistical analysis tools and techniques, including regression analysis, hypothesis testing, and data visualization.
7
Intera by Philips
Sourced in Netherlands, Germany, United States
The Intera is a lab equipment product by Philips. It is a diagnostic imaging device used for magnetic resonance imaging (MRI) procedures. The core function of the Intera is to generate high-quality images of the body's internal structures and organs to assist healthcare professionals in medical diagnosis and treatment planning.
8
C57bl 6 mice by Charles River Laboratories
Sourced in China, United States, Germany, United Kingdom, Canada, Japan, France, Italy, Morocco, Spain, Netherlands, Montenegro, Belgium, Portugal, Ireland, Hungary
The C57BL/6 mouse is a widely used inbred mouse strain. It is a common laboratory mouse model utilized for a variety of research applications.
9
Duolith sd1 by Storz
Sourced in Switzerland
The DUOLITH SD1 is a focused electromagnetic shock wave therapy device designed for medical applications. It generates focused shock waves that can be used for the treatment of various musculoskeletal conditions. The device features an adjustable energy level and can be operated using a user-friendly control panel.
10
V loc 3 0 by Medtronic
Sourced in United States
The V-Loc 3-0 is a suture product manufactured by Medtronic. It is designed for surgical use.

More about "Hypochondriasis"

Hypochondriasis, also known as health anxiety or illness anxiety disorder, is a mental health condition characterized by an excessive and irrational preoccupation with the belief that one has a serious or life-threatening illness.
Individuals with hypochondriasis often become overly focused on minor physical symptoms or bodily functions, interpreting them as signs of a severe medical problem, despite reassurance from healthcare professionals.
This condition can significantly impact a person's quality of life and daily functioning, as they may engage in repeated medical consultations, diagnostic tests, and compulsive health-related behaviors in an attempt to alleviate their concerns.
Effective management of hypochondriasis may involve a combination of cognitive-behavioral therapy (CBT) and, in some cases, medication.
Research on hypochondriasis can be enhanced through the use of AI-driven tools like PubCompare.ai, which can help identify the most accurate and reproducible methods from the literature, preprints, and patents.
By leveraging the power of AI, researchers can optimize their studies and improve outcomes for those affected by this perplexing mental health challenge.
Additionally, related terms and techniques, such as SPSS (Statistical Package for the Social Sciences) version 20 or 22.0, Ingenia MRI systems, DUOLITH SD1 ultrasound therapy devices, and C57BL/6 mouse models, may be useful in the investigation and understanding of hypochondriasis and related conditions.
These tools and methodologies can provide valuable insights and support advancements in the field of hypochondriasis research and treatment.